| dbo:abstract |
شركة سلجين ( بالاتجليزية: Celgene Corporation) شركة تأسست في ولاية ديلاوير ومقرها الرئيسي في سوميت ، نيو جيرسي ،تطور الأدوية الخاصة بالسرطان والالتهابات الالتهابية وتطورها وتسويقها. المنتج الرئيسي للشركة هو ليناليدوميد، بالاشتراك مع ديكساميثازون لعلاج العديد من مرضى المايلوما . الموافقة Revlimid أيضا في الولايات المتحدة لعلاج المرضى الذين يعانون من التي تعتمد على نقل الدم وفقر الدم ، ويرجع ذلك إلى البلدان المنخفضة أو المتوسطة-1-خطر متلازمة خلل التنسج النقوي (MDS) المرتبطة الحذف 5Q الشذوذ الوراثي الخلوي مع أو بدون إضافية الوراثية الخلوية تشوهات. يباع Revlimid من خلال برامج توزيع إدارة المخاطر الخاصة ، لضمان الاستخدام الآمن والمناسب لهذه الأدوية. تمت الموافقة على Vidaza لعلاج المرضى الذين يعانون من MDS. في نوفمبر 2019 ، أعلنت بريستول مايرز سكويب أنها أكملت استحواذها على شركة سلجين. (ar) Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS). (en) Celgene war ein US-amerikanisches Pharmaunternehmen, das sich auf die Herstellung von Arzneimitteln gegen Krebserkrankungen und Krankheiten des Immunsystems spezialisiert hatte. Der Sitz von Celgene befand sich in Summit, New Jersey. Das sich als biopharmaceutical company beschreibende Unternehmen beschäftigte rund 7.500 Mitarbeiter bei einem Umsatz von 15,3 Mrd. Dollar (2018). Celgene arbeitete in den Bereichen Hämatologie, Onkologie und inflammatorische Erkrankungen. Von Celgene entwickelte Immunmodulatoren, so genannte (Immunomodulatory Drugs), die ursprünglich vom Thalidomid-Molekül abgeleitet wurden, zielen auf die Bekämpfung der Krankheitsursachen, nicht auf die Symptome. Wichtigster Vertreter der IMiDs ist Lenalidomid zur Behandlung des multiplen Myeloms. Im Januar 2019 akzeptierte Celgene die Übernahme durch Bristol-Myers Squibb (BMS) für 74 Milliarden US-Dollar. (de) Clegene est une entreprise américaine spécialisée dans l’oncologie. Fondée en 1986 par Sol. J. Barrer, elle est issue d’une scission de Celanese. Elle est rachetée le 5 janvier 2019 par Bristol Myers Squibb. (fr) セルジーン・コーポレーション（英: Celgene Corporation）は、がんや炎症・免疫性疾患の領域における医療用医薬品の研究開発・販売を行うバイオテクノロジー企業。アメリカ合衆国・ニュージャージー州・Summitに本部を置き、世界30カ国以上で事業を展開している。ブリストル・マイヤーズ スクイブの完全子会社。日本法人はセルジーン株式会社。 (ja) Celgene è una società biofarmaceutica americana, con sede centrale a Summit, nel New Jersey, e attività in diversi paesi. È completamente integrata: scopre, sviluppa e commercializza farmaci per il cancro e i disturbi infiammatori. Il prodotto principale dell'azienda è Revlimid (lenalidomide), in associazione con desametasone per il trattamento di pazienti affetti da mieloma multiplo. La società è stata acquisita da Bristol-Myers Squibb nel 2019. È quotata al NASDAQ. (it) Celgene Corporation (NASDAQ: CELG) é uma empresa farmacêutica americana dedicada a Biotecnologia com fins de descobrir, desenvolver e comercializar medicamentos para o câncer e distúrbios inflamatórios, está sediada em Summit, Nova Jersey. (pt) 賽爾基因公司（Celgene Corporation），或譯新基公司，是一家總部位于美國新澤西州的生物科技公司，主要生產抗癌和消炎藥。 (zh) |
| dbo:assets |
3.548E10 (dbd:usDollar) |
| dbo:equity |
6.161E9 (dbd:usDollar) |
| dbo:foundingYear |
1986-01-01 (xsd:gYear) |
| dbo:industry |
dbr:Biotechnology |
| dbo:keyPerson |
dbr:Chief_Executive_Officer dbr:Robert_J._Hugin |
| dbo:location |
dbr:United_States dbr:Summit,_New_Jersey |
| dbo:netIncome |
4.046E9 (dbd:usDollar) |
| dbo:numberOfEmployees |
8852 (xsd:nonNegativeInteger) |
| dbo:parentCompany |
dbr:Bristol_Myers_Squibb |
| dbo:product |
dbr:Abraxane dbr:Idhifa dbr:Imnovid dbr:Thalomid dbr:Pomalyst dbr:Revlimid |
| dbo:revenue |
1.5281E10 (dbd:usDollar) |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Celgene_logo.svg?width=300 |
| dbo:type |
dbr:Subsidiary |
| dbo:wikiPageExternalLink |
https://www.bms.com/ |
| dbo:wikiPageID |
2887610 (xsd:integer) |
| dbo:wikiPageLength |
33104 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1118949017 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbc:Summit,_New_Jersey dbr:Bob_Hugin dbr:Delaware dbr:Hoechst_AG dbr:Ulcerative_colitis dbr:United_Kingdom dbr:United_States dbr:Route_of_administration dbc:Biotechnology_companies_of_the_United_States dbr:Corporate_spin-off dbr:Crohn's_disease dbr:Melphalan dbr:Chief_financial_officer dbr:Chief_operating_officer dbr:Rail_trail dbr:Sutro_Biopharma dbr:Chronic_myelomonocytic_leukemia dbr:GlaxoSmithKline dbr:Multiple_myeloma dbr:Multiple_sclerosis dbc:1980s_initial_public_offerings dbr:Apremilast dbr:Lenalidomide dbr:Starboard_Value dbr:Demcizumab dbr:Bristol-Myers_Squibb dbr:Stockley_Park dbr:Azacitidine dbr:Bristol_Myers_Squibb dbr:CEO dbc:Pharmaceutical_companies_based_in_New_Jersey dbr:Celanese dbr:Windsor,_Berkshire dbr:Linear_park dbr:Agios_Pharmaceuticals dbr:Amgen dbc:2019_mergers_and_acquisitions dbc:American_companies_established_in_1986 dbr:Dr._Reddy's_Laboratories dbr:Executive_Chairman dbr:False_Claims_Act dbr:Fedratinib dbr:Novartis dbr:Ozanimod dbr:Biotech_and_pharmaceutical_companies_in_the_New_York_metropolitan_area dbr:President_(corporate_title) dbr:Refractory_anemia dbc:Companies_formerly_listed_on_the_Nasdaq dbc:Companies_based_in_Union_County,_New_Jersey dbr:Thalidomide dbr:Subsidiary dbr:Stem_cell_therapy dbr:Astrazeneca dbr:Attention_deficit_hyperactivity_disorder dbc:Life_sciences_industry dbc:Bristol_Myers_Squibb dbc:Orphan_drug_companies dbr:Abraxane dbc:1986_establishments_in_New_Jersey dbr:Chief_Executive_Officer dbr:Juno_Therapeutics dbr:Biotechnology dbc:Biotechnology_companies_established_in_1986 dbr:Summit,_New_Jersey dbr:Idhifa dbr:Imnovid dbr:Dexamethasone dbr:Dexmethylphenidate dbc:Pharmaceutical_companies_established_in_1986 dbr:Pomalidomide dbr:Cytogenetic_abnormality dbr:OncoMed dbr:Rahway_Valley_Railroad dbr:Otezla dbr:Specialty_drugs dbr:Thalomid dbr:Pharmaceutical_industry_in_Switzerland dbr:Robert_J._Hugin dbr:Pomalyst dbr:Revlimid dbr:Specialty_pharmacy dbr:Sphingosine-1-phosphate_receptor_modulator dbr:Heathrow_airport dbr:Forbes_magazine dbr:Melphalan_hydrochloride dbr:File:Celgene_logo.svg |
| dbp:assets |
3.548E10 (dbd:usDollar) |
| dbp:equity |
6.161E9 (dbd:usDollar) |
| dbp:founder |
Sol J. Barer (en) |
| dbp:homepage |
https://www.bms.com/ |
| dbp:industry |
dbr:Biotechnology |
| dbp:keyPeople |
dbr:Robert_J._Hugin Mark Alles (en) |
| dbp:location |
dbr:United_States dbr:Summit,_New_Jersey |
| dbp:logo |
150 (xsd:integer) |
| dbp:name |
Celgene (en) Celgene Corporation (en) |
| dbp:netIncome |
4.046E9 (dbd:usDollar) |
| dbp:numEmployees |
8852 (xsd:integer) |
| dbp:parent |
dbr:Bristol_Myers_Squibb |
| dbp:products |
dbr:Abraxane dbr:Idhifa dbr:Imnovid dbr:Thalomid dbr:Pomalyst dbr:Revlimid |
| dbp:revenue |
1.5281E10 (dbd:usDollar) |
| dbp:secCik |
CELG (en) |
| dbp:type |
dbr:Subsidiary |
| dbp:wikiPageUsesTemplate |
dbt:Authority_control dbt:Decrease dbt:Increase dbt:Infobox_company dbt:Portal dbt:Reflist dbt:Short_description dbt:Start_date_and_age dbt:Tree_list dbt:Tree_list/end dbt:Finance_links_historical |
| dbp:wordnet_type |
http://www.w3.org/2006/03/wn/wn20/instances/synset-company-noun-1 |
| dct:subject |
dbc:Summit,_New_Jersey dbc:Biotechnology_companies_of_the_United_States dbc:1980s_initial_public_offerings dbc:Pharmaceutical_companies_based_in_New_Jersey dbc:2019_mergers_and_acquisitions dbc:American_companies_established_in_1986 dbc:Companies_formerly_listed_on_the_Nasdaq dbc:Companies_based_in_Union_County,_New_Jersey dbc:Life_sciences_industry dbc:Bristol_Myers_Squibb dbc:Orphan_drug_companies dbc:1986_establishments_in_New_Jersey dbc:Biotechnology_companies_established_in_1986 dbc:Pharmaceutical_companies_established_in_1986 |
| gold:hypernym |
dbr:Company |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 yago:WikicatBiotechnologyCompanies yago:WikicatBiotechnologyCompaniesOfTheUnitedStates yago:WikicatCompaniesBasedInNewJersey yago:WikicatCompaniesBasedInUnionCounty,NewJersey yago:WikicatCompaniesEstablishedIn1986 yago:WikicatCompaniesInTheNASDAQ-100Index yago:WikicatCompaniesInTheNASDAQBiotechnologyIndex yago:WikicatManufacturingCompaniesEstablishedIn1986 yago:Abstraction100002137 yago:Company108058098 yago:DrugCompany108002578 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity dbo:Organisation yago:SocialGroup107950920 yago:WikicatPharmaceuticalCompanies yago:WikicatPharmaceuticalCompaniesOfTheUnitedStates umbel-rc:Business |
| rdfs:comment |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS). (en) Clegene est une entreprise américaine spécialisée dans l’oncologie. Fondée en 1986 par Sol. J. Barrer, elle est issue d’une scission de Celanese. Elle est rachetée le 5 janvier 2019 par Bristol Myers Squibb. (fr) セルジーン・コーポレーション（英: Celgene Corporation）は、がんや炎症・免疫性疾患の領域における医療用医薬品の研究開発・販売を行うバイオテクノロジー企業。アメリカ合衆国・ニュージャージー州・Summitに本部を置き、世界30カ国以上で事業を展開している。ブリストル・マイヤーズ スクイブの完全子会社。日本法人はセルジーン株式会社。 (ja) Celgene è una società biofarmaceutica americana, con sede centrale a Summit, nel New Jersey, e attività in diversi paesi. È completamente integrata: scopre, sviluppa e commercializza farmaci per il cancro e i disturbi infiammatori. Il prodotto principale dell'azienda è Revlimid (lenalidomide), in associazione con desametasone per il trattamento di pazienti affetti da mieloma multiplo. La società è stata acquisita da Bristol-Myers Squibb nel 2019. È quotata al NASDAQ. (it) Celgene Corporation (NASDAQ: CELG) é uma empresa farmacêutica americana dedicada a Biotecnologia com fins de descobrir, desenvolver e comercializar medicamentos para o câncer e distúrbios inflamatórios, está sediada em Summit, Nova Jersey. (pt) 賽爾基因公司（Celgene Corporation），或譯新基公司，是一家總部位于美國新澤西州的生物科技公司，主要生產抗癌和消炎藥。 (zh) شركة سلجين ( بالاتجليزية: Celgene Corporation) شركة تأسست في ولاية ديلاوير ومقرها الرئيسي في سوميت ، نيو جيرسي ،تطور الأدوية الخاصة بالسرطان والالتهابات الالتهابية وتطورها وتسويقها. المنتج الرئيسي للشركة هو ليناليدوميد، بالاشتراك مع ديكساميثازون لعلاج العديد من مرضى المايلوما . الموافقة Revlimid أيضا في الولايات المتحدة لعلاج المرضى الذين يعانون من التي تعتمد على نقل الدم وفقر الدم ، ويرجع ذلك إلى البلدان المنخفضة أو المتوسطة-1-خطر متلازمة خلل التنسج النقوي (MDS) المرتبطة الحذف 5Q الشذوذ الوراثي الخلوي مع أو بدون إضافية الوراثية الخلوية تشوهات. يباع Revlimid من خلال برامج توزيع إدارة المخاطر الخاصة ، لضمان الاستخدام الآمن والمناسب لهذه الأدوية. تمت الموافقة على Vidaza لعلاج المرضى الذين يعانون من MDS. (ar) Celgene war ein US-amerikanisches Pharmaunternehmen, das sich auf die Herstellung von Arzneimitteln gegen Krebserkrankungen und Krankheiten des Immunsystems spezialisiert hatte. Der Sitz von Celgene befand sich in Summit, New Jersey. Das sich als biopharmaceutical company beschreibende Unternehmen beschäftigte rund 7.500 Mitarbeiter bei einem Umsatz von 15,3 Mrd. Dollar (2018). Celgene arbeitete in den Bereichen Hämatologie, Onkologie und inflammatorische Erkrankungen. Von Celgene entwickelte Immunmodulatoren, so genannte (Immunomodulatory Drugs), die ursprünglich vom Thalidomid-Molekül abgeleitet wurden, zielen auf die Bekämpfung der Krankheitsursachen, nicht auf die Symptome. Wichtigster Vertreter der IMiDs ist Lenalidomid zur Behandlung des multiplen Myeloms. (de) |
| rdfs:label |
Celgene (en) سلجين (ar) Celgene (de) Celgene (it) Celgene (fr) セルジーン (ja) Celgene (pt) 賽爾基因 (zh) |
| owl:sameAs |
freebase:Celgene http://sw.cyc.com/concept/Mx4rvZdBy5wpEbGdrcN5Y29ycA yago-res:Celgene wikidata:Celgene dbpedia-ar:Celgene http://arz.dbpedia.org/resource/سلجين http://azb.dbpedia.org/resource/سلژن dbpedia-de:Celgene dbpedia-et:Celgene dbpedia-fa:Celgene dbpedia-fi:Celgene dbpedia-fr:Celgene dbpedia-it:Celgene dbpedia-ja:Celgene dbpedia-pt:Celgene dbpedia-zh:Celgene https://global.dbpedia.org/id/4zwL3 |
| skos:closeMatch |
http://www.grid.ac/institutes/grid.418722.a http://www.grid.ac/institutes/grid.476224.1 |
| prov:wasDerivedFrom |
wikipedia-en:Celgene?oldid=1118949017&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Celgene_logo.svg |
| foaf:homepage |
https://www.bms.com/ |
| foaf:isPrimaryTopicOf |
wikipedia-en:Celgene |
| foaf:name |
Celgene Corporation (en) |
| is dbo:board of |
dbr:Michael_Bonney |
| is dbo:owner of |
dbr:Abraxis_BioScience |
| is dbo:owningCompany of |
dbr:Abraxis_BioScience |
| is dbo:wikiPageRedirects of |
dbr:CELG dbr:CELG_(NASDAQ) dbr:Celgene_Corp dbr:Celgene_Corp. dbr:Celgene_Corporation dbr:Gloucester_Pharmaceuticals |
| is dbo:wikiPageWikiLink of |
dbr:Cancer_Breakthroughs_2020 dbr:Protein-bound_paclitaxel dbr:Romidepsin dbr:Enigma_(company) dbr:List_of_biotech_and_pharmaceutical_companies_in_the_New_York_metropolitan_area dbr:List_of_companies_by_research_and_development_spending dbr:BeiGene dbr:Bio-1 dbr:Bluebird_bio dbr:Bob_Hugin dbr:List_of_University_of_Virginia_people dbr:List_of_largest_mergers_and_acquisitions dbr:List_of_largest_pharmaceutical_mergers_and_acquisitions dbr:Patrick_Soon-Shiong dbr:Richard_Bagger dbr:University_of_Virginia_Darden_School_of_Business dbr:David_Blech dbr:Repurposing dbr:List_of_human_clusters_of_differentiation dbr:List_of_largest_selling_pharmaceutical_products dbr:List_of_members_of_the_American_Legislative_Exchange_Council dbr:List_of_off-label_promotion_pharmaceutical_settlements dbr:List_of_pharmaceutical_companies dbr:Congressional_Award dbr:Crohn's_&_Colitis_Foundation dbr:Gene_therapy dbr:Psoriatic_arthritis dbr:Sutro_Biopharma dbr:Rachael_A._Honig dbr:Rafael_Fonseca dbr:Enasidenib dbr:Enumeral dbr:Genome_Valley dbr:2018_United_States_Senate_election_in_New_Jersey dbr:Apremilast dbr:Arrakis_Therapeutics dbr:Lenalidomide dbr:Life_Sciences_Foundation dbr:Luspatercept dbr:Mad_Money dbr:Manhattan dbr:Demcizumab dbr:Hariri dbr:Pharma_Documentation_Ring dbr:Porta_Nuova_(Milan) dbr:Medivation dbr:Michael_Bonney dbr:Bristol_Myers_Squibb dbr:Bundesverband_der_Pharmazeutischen_Industrie dbr:Celanese dbr:Tiger_Inn dbr:Abraxis_BioScience dbr:Acceleron_Pharma dbr:Agios_Pharmaceuticals dbr:Amgen dbr:Editas_Medicine dbr:Evercore dbr:False_Claims_Act dbr:Fedratinib dbr:First_100_days_of_Donald_Trump's_presidency dbr:GlobeImmune dbr:List_of_S&P_500_companies dbr:Reuben_Guttman dbr:The_Blech_Effect dbr:Arena_Pharmaceuticals dbr:AstraZeneca dbr:Abingworth_(company) dbr:Juno_Therapeutics dbr:Bionor_Pharma dbr:Summit,_New_Jersey dbr:Economy_of_New_York_City dbr:Economy_of_San_Diego dbr:Ed_Mitzen dbr:Reagan-Udall_Foundation dbr:CC-1088 dbr:Human_Longevity dbr:Immunomodulatory_imide_drug dbr:Kirkland_&_Ellis dbr:Midtown_Manhattan dbr:Milan dbr:NantHealth dbr:Nasdaq-100 dbr:New_York_City dbr:New_York_metropolitan_area dbr:OncoMed dbr:CELG dbr:CELG_(NASDAQ) dbr:Structural_Genomics_Consortium dbr:Nextbio dbr:FOLFIRINOX dbr:Sam_Dryden dbr:FinnGen dbr:Multiple_Myeloma_Research_Consortium dbr:Pharmaceutical_Advertising_Advisory_Board dbr:Raymond_C._Stevens dbr:List_of_companies_of_the_United_States_by_state dbr:Speculation_about_Donald_Trump's_Cabinet dbr:Celgene_Corp dbr:Celgene_Corp. dbr:Celgene_Corporation dbr:Gloucester_Pharmaceuticals |
| is dbp:owner of |
dbr:Abraxis_BioScience |
| is foaf:primaryTopic of |
wikipedia-en:Celgene |
